Compare Codexis, Inc. with Similar Stocks
Stock DNA
Specialty Chemicals
USD 136 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.42
-158.13%
3.54
Revenue and Profits:
Net Sales:
39 Million
(Quarterly Results - Dec 2025)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.44%
0%
-2.44%
6 Months
-35.74%
0%
-35.74%
1 Year
-41.39%
0%
-41.39%
2 Years
-50.77%
0%
-50.77%
3 Years
-58.87%
0%
-58.87%
4 Years
-92.36%
0%
-92.36%
5 Years
-92.29%
0%
-92.29%
Codexis, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.51%
EBIT Growth (5y)
-196.76%
EBIT to Interest (avg)
-40.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.66
Tax Ratio
0.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.32%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.54
EV to EBIT
-2.01
EV to EBITDA
-2.33
EV to Capital Employed
5.41
EV to Sales
2.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-268.91%
ROE (Latest)
-158.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 42 Schemes (36.06%)
Foreign Institutions
Held by 49 Foreign Institutions (6.52%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
38.90
8.60
352.33%
Operating Profit (PBDIT) excl Other Income
16.20
-16.90
195.86%
Interest
0.00
0.00
Exceptional Items
-3.40
0.00
Consolidate Net Profit
9.60
-19.60
148.98%
Operating Profit Margin (Excl OI)
358.90%
-2,203.10%
256.20%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 352.33% vs -43.79% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 148.98% vs -47.37% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
70.40
59.30
18.72%
Operating Profit (PBDIT) excl Other Income
-30.00
-50.20
40.24%
Interest
0.00
0.00
Exceptional Items
-3.70
-7.10
47.89%
Consolidate Net Profit
-44.00
-65.30
32.62%
Operating Profit Margin (Excl OI)
-544.60%
-983.30%
43.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 18.72% vs -15.41% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 32.62% vs 14.30% in Dec 2024
About Codexis, Inc. 
Codexis, Inc.
Specialty Chemicals
Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.
Company Coordinates 
Company Details
200 Penobscot Dr , REDWOOD CITY CA : 94063-4718
Registrar Details






